LAG3 expression widely suppresses anti-tumor immunity directly by impairing T/NK cells, and indirectly through impeding CD4+ T-cell functions via binding to MHC class II (MHC II) with a higher affinity than CD4 [131]. The gene discussed is LAG3; the disease is neoplasm.